Pharsight

1. List of Androgel drug patents

Application	Filing Date	Opposition Party	Legal Status
EP06836341A	2013-08-21	Oser, Andreas	Opposition rejected

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741881	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8729057	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8466136	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8759329	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8486925	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8754070	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8466137	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8466138	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 29 April, 2011

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

Strength	Dosage	Availability
1.62% (20.25MG/1.25GM ACTUATION)	GEL, METERED;TRANSDERMAL	Prescription
1.62% (20.25MG/1.25GM PACKET)	GEL;TRANSDERMAL	Discontinued
1.62% (40.5MG/2.5GM PACKET)	GEL;TRANSDERMAL	Discontinued

ANDROGEL family patents

United States

European Union

Poland

Slovenia

Japan

Denmark

Spain

Norway

Portugal

Cyprus

Georgia

Canada

Korea, Republic of

Ukraine

Brazil

Hong Kong

Turkey

Lithuania

China

Morocco

Croatia

New Zealand

Australia

South Africa

Ecuador

Tunisia

Israel

^new

2. List of Oriahnn (copackaged) drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11542239	ABBVIE	Elagolix sodium compositions and processes	Jul, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023
New Product (NP)	May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 29 May, 2020

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	CAPSULE;ORAL	Prescription

3. List of Orilissa drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11542239	ABBVIE	Elagolix sodium compositions and processes	Jul, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
150 mg and 200 mg	25 Jul, 2022	9		01 Sep, 2036

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription
EQ 200MG BASE	TABLET;ORAL	Prescription

4. List of Rinvoq drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11535625	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11524964	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11535624	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11535626	ABBVIE	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof	Oct, 2036 (13 years from now)
US11607411	ABBVIE	Methods of treating Crohn's disease and ulcerative colitis	Mar, 2038 (14 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 14, 2024
New Chemical Entity Exclusivity (NCE)	Aug 16, 2024

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products,...

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
15MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
45MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

5. List of Tricor drug patents

Application	Filing Date	Opposition Party	Legal Status
EP03723781A	2007-07-25	Abraxis BioScience, Inc.	Patent maintained as amended
EP03723781A	2007-07-20	Baxter Healthcare Corporation	Patent maintained as amended

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7276249	ABBVIE	Nanoparticulate fibrate formulations	Feb, 2023 (3 months ago)
US7320802	ABBVIE	Methods of treatment using nanoparticulate fenofibrate compositions	Feb, 2023 (3 months ago)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 05 November, 2004

Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hype...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
48 mg	01 Jul, 2008	1	05 Apr, 2012	21 Feb, 2023	Extinguished
145 mg	19 Oct, 2007	1		21 Feb, 2023	Extinguished

Strength	Dosage	Availability
48MG	TABLET;ORAL	Prescription
145MG	TABLET;ORAL	Prescription

TRICOR family patents

United States

Japan

European Union

Canada

Australia

Austria

Germany

Spain

Korea, Republic of

Denmark

Argentina

Taiwan

China

Portugal

Cyprus

Uruguay

Mexico

New Zealand

Norway

Brazil

Morocco

Malaysia

South Africa

Tunisia

Singapore

Israel

^new

6. List of Trilipix drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7259186	ABBVIE	Salts of fenofibric acid and pharmaceutical formulations thereof	Jan, 2025 (1 year, 6 months from now)

Drugs and Companies using CHOLINE FENOFIBRATE ingredient

Market Authorisation Date: 15 December, 2008

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
45 mg	02 Sep, 2009	1	07 Sep, 2016	07 Jan, 2025	Extinguished
135 mg	01 Sep, 2009	1	07 Sep, 2016	07 Jan, 2025	Extinguished

Strength	Dosage	Availability
EQ 45MG FENOFIBRIC ACID	CAPSULE, DELAYED RELEASE;ORAL	Prescription
EQ 135MG FENOFIBRIC ACID	CAPSULE, DELAYED RELEASE;ORAL	Prescription

TRILIPIX family patents

United States

European Union

Australia

China

Russia

Canada

Austria

Germany

Spain

Mexico

Japan

^new

7. List of Venclexta drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590128	ABBVIE	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	Sep, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	May 15, 2026
M (M)	Oct 16, 2023

Drugs and Companies using VENETOCLAX ingredient

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of aml by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine to adults 75 years or older or having certain comorbidities per a dose ramp-up including an in...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg, 50 mg and 100 mg	13 Apr, 2020	2		29 Jan, 2032

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

8. List of Vraylar drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE49302	ABBVIE	Pharmaceutical formulations containing dopamine receptor ligands	Jul, 2029 (6 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	Dec 16, 2025

Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 September, 2015

Treatment: Treatment of schizophrenia with cariprazine; Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of acute manic or mixed episodes associated with bipolar i ...

Dosage: CAPSULE;ORAL